RUNX2 and neoplasm: For example, the interaction between RUNX2 and core binding factor beta (CBFβ) is a critical driver of malignancy in canine osteosarcoma, and disrupting this interaction using small-molecule allosteric inhibitors can suppress tumor cell growth, induce apoptosis, and enhance the effects of chemotherapy [64].